Literature DB >> 21102525

Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.

M Marzec1, X Liu, W Wong, Y Yang, T Pasha, K Kantekure, P Zhang, A Woetmann, M Cheng, N Odum, M A Wasik.   

Abstract

The mechanisms of malignant cell transformation mediated by the oncogenic anaplastic lymphoma kinase (ALK) tyrosine kinase remain only partially understood. In this study, we report that T-cell lymphoma (TCL) cells carrying the nucleophosmin (NPM)/ALK fusion protein (ALK+ TCL) strongly express hypoxia-induced factor 1α (HIF1α) mRNA, even under normoxic conditions, and markedly upregulate HIF1α protein expression under hypoxia. HIF1α expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as shown in BaF3 cells transfected with wild-type NPM/ALK and kinase-inactive NPM/ALK K210R mutant and by the inhibition of the NPM/ALK function in ALK+ TCL cells by a small-molecule ALK inhibitor. NPM/ALK induces HIF1α expression by upregulating its gene transcription through its key signal transmitter signal transducer and activator of transcription 3 (STAT3), which binds to the HIF1α gene promoter as shown by the chromatin immunoprecipitation assay and is required for HIF1α gene expression as demonstrated by its small interfering RNA-mediated depletion. In turn, depletion of HIF1α increases mammalian target of rapamycin complex 1 activation, cell growth and proliferation and decreases vascular endothelial growth factor synthesis. These results identify a novel cell-transforming property of NPM/ALK, namely its ability to induce the expression of HIF1α, a protein with an important role in carcinogenesis. These results also provide another rationale to therapeutically target NPM/ALK and STAT3 in ALK+ TCL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102525     DOI: 10.1038/onc.2010.505

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

Review 2.  Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Authors:  Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

3.  Identification of HIF-1α promoter and expression regulation of HIF-1α gene by LPS and hypoxia in zebrafish.

Authors:  Shasha Liu; Kecheng Zhu; Nan Chen; Weimin Wang; Huanling Wang
Journal:  Fish Physiol Biochem       Date:  2013-02-08       Impact factor: 2.794

4.  EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.

Authors:  Jaemoon Koh; Ji-Young Jang; Bhumsuk Keam; Sehui Kim; Moon-Young Kim; Heounjeong Go; Tae Min Kim; Dong-Wan Kim; Chul-Woo Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 5.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 6.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Authors:  Daniela Di Paolo; Chiara Ambrogio; Fabio Pastorino; Chiara Brignole; Cinzia Martinengo; Roberta Carosio; Monica Loi; Gabriella Pagnan; Laura Emionite; Michele Cilli; Domenico Ribatti; Theresa M Allen; Roberto Chiarle; Mirco Ponzoni; Patrizia Perri
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

8.  Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.

Authors:  Dalia Elsers; Doaa F Temerik; Alia M Attia; A Hadia; Marwa T Hussien
Journal:  J Pathol Transl Med       Date:  2021-05-11

9.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.

Authors:  Joel D Pearson; Jason K H Lee; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  J Signal Transduct       Date:  2012-07-18

10.  Development of lymphoproliferative diseases by hypoxia inducible factor-1alpha is associated with prolonged lymphocyte survival.

Authors:  Eisaburo Sueoka; Naoko Sueoka-Aragane; Akemi Sato; Masaru Ide; Hideaki Nakamura; Yusuke Sotomaru; Choji Taya; Hiromichi Yonekawa; Tomoyuki Kitagawa; Yasushi Kubota; Shinya Kimura; Kei Nakachi; Keiji Tanimoto
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.